These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 9706025)
1. ATP is a potent stimulator of the activation and formation of rodent osteoclasts. Morrison MS; Turin L; King BF; Burnstock G; Arnett TR J Physiol; 1998 Sep; 511 ( Pt 2)(Pt 2):495-500. PubMed ID: 9706025 [TBL] [Abstract][Full Text] [Related]
2. ATP and UTP at low concentrations strongly inhibit bone formation by osteoblasts: a novel role for the P2Y2 receptor in bone remodeling. Hoebertz A; Mahendran S; Burnstock G; Arnett TR J Cell Biochem; 2002; 86(3):413-9. PubMed ID: 12210747 [TBL] [Abstract][Full Text] [Related]
3. Extracellular ADP is a powerful osteolytic agent: evidence for signaling through the P2Y(1) receptor on bone cells. Hoebertz A; Meghji S; Burnstock G; Arnett TR FASEB J; 2001 May; 15(7):1139-48. PubMed ID: 11344082 [TBL] [Abstract][Full Text] [Related]
4. Adenosine triphosphate stimulates human osteoclast activity via upregulation of osteoblast-expressed receptor activator of nuclear factor-kappa B ligand. Buckley KA; Hipskind RA; Gartland A; Bowler WB; Gallagher JA Bone; 2002 Nov; 31(5):582-90. PubMed ID: 12477572 [TBL] [Abstract][Full Text] [Related]
5. Urocortin is a novel regulator of osteoclast differentiation and function through inhibition of a canonical transient receptor potential 1-like cation channel. Combs CE; Fuller K; Kumar H; Albert AP; Pirianov G; McCormick J; Locke IC; Chambers TJ; Lawrence KM J Endocrinol; 2012 Feb; 212(2):187-97. PubMed ID: 22083217 [TBL] [Abstract][Full Text] [Related]
6. Quercetin suppresses bone resorption by inhibiting the differentiation and activation of osteoclasts. Woo JT; Nakagawa H; Notoya M; Yonezawa T; Udagawa N; Lee IS; Ohnishi M; Hagiwara H; Nagai K Biol Pharm Bull; 2004 Apr; 27(4):504-9. PubMed ID: 15056855 [TBL] [Abstract][Full Text] [Related]
8. The Escherichia coli chaperonin 60 (groEL) is a potent stimulator of osteoclast formation. Reddi K; Meghji S; Nair SP; Arnett TR; Miller AD; Preuss M; Wilson M; Henderson B; Hill P J Bone Miner Res; 1998 Aug; 13(8):1260-6. PubMed ID: 9718194 [TBL] [Abstract][Full Text] [Related]
9. Cytokine-induced nitric oxide inhibits bone resorption by inducing apoptosis of osteoclast progenitors and suppressing osteoclast activity. van't Hof RJ; Ralston SH J Bone Miner Res; 1997 Nov; 12(11):1797-804. PubMed ID: 9383684 [TBL] [Abstract][Full Text] [Related]
10. Osteoblasts mediate insulin-like growth factor-I and -II stimulation of osteoclast formation and function. Hill PA; Reynolds JJ; Meikle MC Endocrinology; 1995 Jan; 136(1):124-31. PubMed ID: 7828521 [TBL] [Abstract][Full Text] [Related]
11. Inhibitory effect of menaquinone-7 (vitamin K2) on osteoclast-like cell formation and osteoclastic bone resorption in rat bone tissues in vitro. Yamaguchi M; Ma ZJ Mol Cell Biochem; 2001 Dec; 228(1-2):39-47. PubMed ID: 11855740 [TBL] [Abstract][Full Text] [Related]
12. Direct and indirect actions of fibroblast growth factor 2 on osteoclastic bone resorption in cultures. Kawaguchi H; Chikazu D; Nakamura K; Kumegawa M; Hakeda Y J Bone Miner Res; 2000 Mar; 15(3):466-73. PubMed ID: 10750561 [TBL] [Abstract][Full Text] [Related]
14. Hypoxia is a major stimulator of osteoclast formation and bone resorption. Arnett TR; Gibbons DC; Utting JC; Orriss IR; Hoebertz A; Rosendaal M; Meghji S J Cell Physiol; 2003 Jul; 196(1):2-8. PubMed ID: 12767036 [TBL] [Abstract][Full Text] [Related]
15. Bone resorption inhibitor alendronate normalizes the reduced bone thickness of TRPV5(-/-) mice. Nijenhuis T; van der Eerden BC; Hoenderop JG; Weinans H; van Leeuwen JP; Bindels RJ J Bone Miner Res; 2008 Nov; 23(11):1815-24. PubMed ID: 18597625 [TBL] [Abstract][Full Text] [Related]
16. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption. Michael H; Härkönen PL; Väänänen HK; Hentunen TA J Bone Miner Res; 2005 Dec; 20(12):2224-32. PubMed ID: 16294275 [TBL] [Abstract][Full Text] [Related]
17. Calcitonin responsiveness and receptor expression in porcine and murine osteoclasts: a comparative study. Galvin RJ; Bryan P; Venugopalan M; Smith DP; Thomas JE Bone; 1998 Sep; 23(3):233-40. PubMed ID: 9737345 [TBL] [Abstract][Full Text] [Related]
18. Selective toxic effects of tamoxifen on osteoclasts: comparison with the effects of oestrogen. Arnett TR; Lindsay R; Kilb JM; Moonga BS; Spowage M; Dempster DW J Endocrinol; 1996 Jun; 149(3):503-8. PubMed ID: 8691109 [TBL] [Abstract][Full Text] [Related]
19. Lack of effect of adenosine on the function of rodent osteoblasts and osteoclasts in vitro. Hajjawi MO; Patel JJ; Corcelli M; Arnett TR; Orriss IR Purinergic Signal; 2016 Jun; 12(2):247-58. PubMed ID: 26861849 [TBL] [Abstract][Full Text] [Related]
20. Direct effect of calcium channel antagonists on osteoclast function: alterations in bone resorption and intracellular calcium concentrations. Ritchie CK; Maercklein PB; Fitzpatrick LA Endocrinology; 1994 Sep; 135(3):996-1003. PubMed ID: 8070395 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]